Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15
The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Abstract
An old cancer drug's degrading new look: Typically, cancer drugs that help only a small number of patients in clinical trials are not pursued. This might change in a future world of precision medicine, where biomarkers will match specific drugs to the patients most likely to respond. Han et al. identified the mechanism of action of a cancer drug called indisulam, a sulfonamide tested previously in patients with solid tumors. Indisulam and related sulfonamides killed cells by disrupting precursor mRNA splicing. The drugs targeted a specific RNA splicing factor for degradation by “gluing” it to the CUL4-DCAF15 ubiquitin ligase. Experiments with cancer cell lines suggest that future clinical trials of these drugs should focus on leukemias and lymphomas with high DCAF15 expression levels. Science , this issue p. eaal3755
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, aryl sulphonamides degrade the essential RNA-binding protein RBM39 by engaging DCAF15, the substrate receptor of the CRL4DCAF15 E3 ubiquitin ligase13–15.”
From The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K (2020) · cites this paper as [13]
In the citing paper
“it took two decades to determine that indisulam, and the related sulfonamides e7820 and chloroquinoxaline sulfonamide (cQS), were in fact glue degraders that targeted the splicing factor RBM39 (Han et al. 2017;uehara et al. 2017).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Han et al. 2017
In the citing paper
“indisulam facilitated an interaction between RBM39 and DcAF15, a substrate receptor component of the cRl4 DcAF15 ligase complex (Han et al. 2017;uehara et al. 2017).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Han et al. 2017
In the citing paper
“However, sulfonamides such as indisulam and similar SPlAMs were serendipitously discovered to degrade RBM39 by stabilizing its native interaction with cRl4 DcAF15 (Han et al. 2017; uehara et al. 2017) (Figure 4A).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Han et al. 2017
In the citing paper
“The same MG mechanism has subsequently been revealed for antitumor aryl-sulfonamides, which reprograms another CRL4 substrate receptor, DCAF15, to bind and degrade certain RNA-binding proteins21–26.”
From Defining molecular glues with a dual-nanobody cannabidiol sensor (2022) · cites this paper as [21]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., & Salzberg, S. L. (2013) · Genome Biology · doi:10.1186/gb-2013-14-4-r36 · Cited by 12,668 · cited 1×
“8) (52) to human reference genome (hg19) along with the gene annotation data downloaded from Illumina’s iGenomes (http://support.”
MethodMass Spectrometric Sequencing of Proteins from Silver-Stained Polyacrylamide Gels
Shevchenko, A., Wilm, M., Vorm, O., & Mann, M. (1996) · Analytical Chemistry · doi:10.1021/ac950914h · Cited by 8,995
Eng, J. K., McCormack, A. L., & Yates, J. R. (1994) · Journal of the American Society for Mass Spectrometry · doi:10.1016/1044-0305(94)80016-2 · Cited by 6,484 · cited 2×
“As peptides eluted they were subjected to electrospray ionization and then entered into an LTQ Orbitrap Velos Pro ion-trap mass spectrometer (Thermo Fisher Scientific, Waltham, MA).”
MethodNGS QC Toolkit: A Toolkit for Quality Control of Next Generation Sequencing Data
Patel, R. K., & Jain, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030619 · Cited by 2,917
Function and regulation of cullin–RING ubiquitin ligases
Petroski, M. D., & Deshaies, R. J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1547 · Cited by 2,148
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990 · cited 7×
“In many cases, ubiquitin is added to substrates by cullinRING ligases (CRLs), which are multisubunit ubiquitin ligases (23).”
BackgroundInfluentialLenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
Mechanism of auxin perception by the TIR1 ubiquitin ligase
Tan, X., Calderon-Villalobos, L. I. A., Sharon, M., Zheng, C., Robinson, C. V., Estelle, M., & Zheng, N. (2007) · Nature · doi:10.1038/nature05731 · Cited by 1,688 · cited 1×
“This is the same mechanism by which the plant hormone auxin acts like “molecular glue” to enhance an interaction between the E3 ubiquitin ligase receptor TIR1 and its substrates (43).”
Background
Cited by
PROTAC targeted protein degraders: the past is prologue
Békés, M., Langley, D. R., & Crews, C. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00371-6 · Cited by 3,395
Goodall, G. J., & Wickramasinghe, V. O. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00306-0 · Cited by 1,066
Targeted protein degradation: expanding the toolbox
Schapira, M., Calabrese, M. F., Bullock, A. N., & Crews, C. M. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0047-y · Cited by 960
Roles and mechanisms of alternative splicing in cancer — implications for care
Bonnal, S. C., López-Oreja, I., & Valcárcel, J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0350-x · Cited by 731
Advancing targeted protein degradation for cancer therapy
Dale, B., Cheng, M., Park, K.-S., Kaniskan, H. Ü., Xiong, Y., & Jin, J. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00365-x · Cited by 632
Ubiquitylation at the crossroads of development and disease
Rape, M. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.83 · Cited by 614
RNA splicing dysregulation and the hallmarks of cancer
Bradley, R. K., & Anczuków, O. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00541-7 · Cited by 579
PROTACs: An Emerging Therapeutic Modality in Precision Medicine
Nalawansha, D. A., & Crews, C. M. (2020) · Cell Chemical Biology · doi:10.1016/j.chembiol.2020.07.020 · Cited by 490
Development of targeted protein degradation therapeutics
Chamberlain, P. P., & Hamann, L. G. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0362-y · Cited by 489
Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16
Zhang, X., Crowley, V. M., Wucherpfennig, T. G., Dix, M. M., & Cravatt, B. F. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0279-5 · Cited by 487
Targeted protein degradation: from mechanisms to clinic
Tsai, J. M., Nowak, R. P., Ebert, B. L., & Fischer, E. S. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00729-9 · Cited by 438
“…the aryl sulfonamide indisulam (E7070) was identified as a molecular glue that facilitates a neo-interaction between the DDB1 and cullin-associated factor DCAF15 as part of the CUL4–DDB1–DDA1– DCAF15 (CRL4 DCAF15 ) ligase complex and the splicing factor RBM39, leading to RBM39 degradation 93,94 .”
A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader
Huang, H.-T., Dobrovolsky, D., Paulk, J., Yang, G., Weisberg, E. L., Doctor, Z. M., Buckley, D. L., Cho, J.-H., Ko, E., Jang, J., et al. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.10.005 · Cited by 437
“, 2014) and the splicing inhibitor sulfonamides (SPLAMs) (Han et al., 2017) at redirecting the substrate profile of an E3 ubiquitin ligase.”
BackgroundThe CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K
Słabicki, M., Kozicka, Z., Petzold, G., Li, Y.-D., Manojkumar, M., Bunker, R. D., Donovan, K. A., Sievers, Q. L., Koeppel, J., Suchyta, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2374-x · Cited by 433
Semiconducting polymer nano-PROTACs for activatable photo-immunometabolic cancer therapy
Zhang, C., Zeng, Z., Cui, D., He, S., Jiang, Y., Li, J., Huang, J., & Pu, K. (2021) · Nature Communications · doi:10.1038/s41467-021-23194-w · Cited by 411
E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones
Ishida, T., & Ciulli, A. (2021) · SLAS Discovery · doi:10.1177/2472555220965528 · Cited by 380
Urbanski, L. M., Leclair, N., & Anczuków, O. (2018) · WIREs RNA · doi:10.1002/wrna.1476 · Cited by 389
Rational discovery of molecular glue degraders via scalable chemical profiling
Mayor-Ruiz, C., Bauer, S., Brand, M., Kozicka, Z., Siklos, M., Imrichova, H., Kaltheuner, I. H., Hahn, E., Seiler, K., Koren, A., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0594-x · Cited by 369
Molecular Glues for Targeted Protein Degradation: From Serendipity to Rational Discovery
Dong, G., Ding, Y., He, S., & Sheng, C. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00895 · Cited by 369
Alternative splicing and related RNA binding proteins in human health and disease
Tao, Y., Zhang, Q., Wang, H., Yang, X., & Mu, H. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01734-2 · Cited by 320
Antibody–PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4
Maneiro, M., Forte, N., Shchepinova, M. M., Kounde, C. S., Chudasama, V., Baker, J. R., & Tate, E. W. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00285 · Cited by 350
Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia
Wang, E., Lu, S. X., Pastore, A., Chen, X., Imig, J., Chun-Wei Lee, S., Hockemeyer, K., Ghebrechristos, Y. E., Yoshimi, A., Inoue, D., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.01.010 · Cited by 338
“To resemble disease burden in patients, we waited until onset of disease, and subsequently mice were treated for 13 consecutive daily treatments of either vehicle or 25 mg/kg indisulam, a previously described dose (Han et al., 2017).”
BackgroundMethodZoppi, V., Hughes, S. J., Maniaci, C., Testa, A., Gmaschitz, T., Wieshofer, C., Koegl, M., Riching, K. M., Daniels, D. L., Spallarossa, A., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01413 · Cited by 336
WD40 repeat domain proteins: a novel target class?
Schapira, M., Tyers, M., Torrent, M., & Arrowsmith, C. H. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.179 · Cited by 335
Targeted protein degradation: advances in drug discovery and clinical practice
Zhong, G., Chang, X., Xie, W., & Zhou, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02004-x · Cited by 326
The role of alternative splicing in cancer: From oncogenesis to drug resistance
Sciarrillo, R., Wojtuszkiewicz, A., Assaraf, Y. G., Jansen, G., Kaspers, G. J. L., Giovannetti, E., & Cloos, J. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100728 · Cited by 307
Arginine reprograms metabolism in liver cancer via RBM39
Mossmann, D., Müller, C., Park, S., Ryback, B., Colombi, M., Ritter, N., Weißenberger, D., Dazert, E., Coto-Llerena, M., Nuciforo, S., et al. (2023) · Cell · doi:10.1016/j.cell.2023.09.011 · Cited by 293
Aberrant RNA Splicing in Cancer
Escobar-Hoyos, L., Knorr, K., & Abdel-Wahab, O. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050407 · Cited by 302
Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation
Fong, J. Y., Pignata, L., Goy, P.-A., Kawabata, K. C., Lee, S. C.-W., Koh, C. M., Musiani, D., Massignani, E., Kotini, A. G., Penson, A., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.07.003 · Cited by 270
Patch-Seq Links Single-Cell Transcriptomes to Human Islet Dysfunction in Diabetes
Camunas-Soler, J., Dai, X.-Q., Hang, Y., Bautista, A., Lyon, J., Suzuki, K., Kim, S. K., Quake, S. R., & MacDonald, P. E. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.04.005 · Cited by 291
Pharmacologic modulation of RNA splicing enhances anti-tumor immunity
Lu, S. X., De Neef, E., Thomas, J. D., Sabio, E., Rousseau, B., Gigoux, M., Knorr, D. A., Greenbaum, B., Elhanati, Y., Hogg, S. J., et al. (2021) · Cell · doi:10.1016/j.cell.2021.05.038 · Cited by 284
Regulation of pre-mRNA splicing: roles in physiology and disease, and therapeutic prospects
Rogalska, M. E., Vivori, C., & Valcárcel, J. (2023) · Nature Reviews Genetics · doi:10.1038/s41576-022-00556-8 · Cited by 265
Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs
Alabi, S. B., & Crews, C. M. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100647 · Cited by 261
Recent advances in the synthesis of smart hydrogels
Sikdar, P., Uddin, M. M., Dip, T. M., Islam, S., Hoque, M. S., Dhar, A. K., & Wu, S. (2021) · Materials Advances · doi:10.1039/d1ma00193k · Cited by 254
Multispecific drugs herald a new era of biopharmaceutical innovation
Deshaies, R. J. (2020) · Nature · doi:10.1038/s41586-020-2168-1 · Cited by 262
Molecular Glues: The Adhesive Connecting Targeted Protein Degradation to the Clinic
Sasso, J. M., Tenchov, R., Wang, D., Johnson, L. S., Wang, X., & Zhou, Q. A. (2023) · Biochemistry · doi:10.1021/acs.biochem.2c00245 · Cited by 246
Structural basis of indisulam-mediated RBM39 recruitment to DCAF15 E3 ligase complex
Bussiere, D. E., Xie, L., Srinivas, H., Shu, W., Burke, A., Be, C., Zhao, J., Godbole, A., King, D., Karki, R. G., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-019-0411-6 · Cited by 257
PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics
Khan, S., He, Y., Zhang, X., Yuan, Y., Pu, S., Kong, Q., Zheng, G., & Zhou, D. (2020) · Oncogene · doi:10.1038/s41388-020-1336-y · Cited by 252
“, indisulam) can induce the degradation of neosubstrates by recruiting them to CRBN or DCAF15, respectively [69, 84, 85].”
BackgroundManiaci, C., Hughes, S. J., Testa, A., Chen, W., Lamont, D. J., Rocha, S., Alessi, D. R., Romeo, R., & Ciulli, A. (2017) · Nature Communications · doi:10.1038/s41467-017-00954-1 · Cited by 245
Targeted protein degradation for cancer therapy
Hinterndorfer, M., Spiteri, V. A., Ciulli, A., & Winter, G. E. (2025) · Nature Reviews Cancer · doi:10.1038/s41568-025-00817-8 · Cited by 210
Wang, E., & Aifantis, I. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.04.011 · Cited by 240
de Wispelaere, M., Du, G., Donovan, K. A., Zhang, T., Eleuteri, N. A., Yuan, J. C., Kalabathula, J., Nowak, R. P., Fischer, E. S., Gray, N. S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11429-w · Cited by 237
PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery
Gu, S., Cui, D., Chen, X., Xiong, X., & Zhao, Y. (2018) · BioEssays · doi:10.1002/bies.201700247 · Cited by 231
E3 Ligase Ligands in Successful PROTACs: An Overview of Syntheses and Linker Attachment Points
Bricelj, A., Steinebach, C., Kuchta, R., Gütschow, M., & Sosič, I. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.707317 · Cited by 214
Proteolysis‐targeting chimeras in drug development: A safety perspective
Moreau, K., Coen, M., Zhang, A. X., Pachl, F., Castaldi, M. P., Dahl, G., Boyd, H., Scott, C., & Newham, P. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15014 · Cited by 229
“Novartis has recently solved the complex structure of DCAF15-DDB1-DDA1-Indisulam-RBM39 and from this work identified the precise mechanism by which indisulam mediates interaction between RBM39 and DCAF15 (Han et al., 2017).”
BackgroundInfluentialSpliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer
Bowling, E. A., Wang, J. H., Gong, F., Wu, W., Neill, N. J., Kim, I. S., Tyagi, S., Orellana, M., Kurley, S. J., Dominguez-Vidaña, R., et al. (2021) · Cell · doi:10.1016/j.cell.2020.12.031 · Cited by 224
Targeted protein degradation via intramolecular bivalent glues
Hsia, O., Hinterndorfer, M., Cowan, A. D., Iso, K., Ishida, T., Sundaramoorthy, R., Nakasone, M. A., Imrichova, H., Schätz, C., Rukavina, A., et al. (2024) · Nature · doi:10.1038/s41586-024-07089-6 · Cited by 222
Structural complementarity facilitates E7820-mediated degradation of RBM39 by DCAF15
Faust, T. B., Yoon, H., Nowak, R. P., Donovan, K. A., Li, Z., Cai, Q., Eleuteri, N. A., Zhang, T., Gray, N. S., & Fischer, E. S. (2020) · Nature Chemical Biology · doi:10.1038/s41589-019-0378-3 · Cited by 218
Ubiquitin ligases: guardians of mammalian development
Cruz Walma, D. A., Chen, Z., Bullock, A. N., & Yamada, K. M. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00448-5 · Cited by 211
Prospective discovery of small molecule enhancers of an E3 ligase-substrate interaction
Simonetta, K. R., Taygerly, J., Boyle, K., Basham, S. E., Padovani, C., Lou, Y., Cummins, T. J., Yung, S. L., von Soly, S. K., Kayser, F., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09358-9 · Cited by 217
Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation
Lv, L., Chen, P., Cao, L., Li, Y., Zeng, Z., Cui, Y., Wu, Q., Li, J., Wang, J.-H., Dong, M.-Q., et al. (2020) · eLife · doi:10.7554/elife.59994 · Cited by 215
Self-citationProximity-Based Modalities for Biology and Medicine
Liu, X., & Ciulli, A. (2023) · ACS Central Science · doi:10.1021/acscentsci.3c00395 · Cited by 196
Cancer the‘RBP’eutics–RNA-binding proteins as therapeutic targets for cancer
Mohibi, S., Chen, X., & Zhang, J. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.07.001 · Cited by 199
Rational Chemical Design of Molecular Glue Degraders
Toriki, E. S., Papatzimas, J. W., Nishikawa, K., Dovala, D., Frank, A. O., Hesse, M. J., Dankova, D., Song, J.-G., Bruce-Smythe, M., Struble, H., et al. (2023) · ACS Central Science · doi:10.1021/acscentsci.2c01317 · Cited by 184
Chasing molecular glue degraders: screening approaches
Domostegui, A., Nieto-Barrado, L., Perez-Lopez, C., & Mayor-Ruiz, C. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00197g · Cited by 200
Unifying principles of bifunctional, proximity-inducing small molecules
Gerry, C. J., & Schreiber, S. L. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0469-1 · Cited by 199
Molecular glues for protein-protein interactions: Progressing toward a new dream
Konstantinidou, M., & Arkin, M. R. (2024) · Cell Chemical Biology · doi:10.1016/j.chembiol.2024.04.002 · Cited by 187
Yang, J., Li, Y., Aguilar, A., Liu, Z., Yang, C.-Y., & Wang, S. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00846 · Cited by 190
PROTACs: A novel strategy for cancer therapy
Liu, J., Ma, J., Liu, Y., Xia, J., Li, Y., Wang, Z. P., & Wei, W. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.02.006 · Cited by 186
Harnessing the Power of Proteolysis for Targeted Protein Inactivation
Verma, R., Mohl, D., & Deshaies, R. J. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.01.010 · Cited by 185
Targeted protein degradation as a powerful research tool in basic biology and drug target discovery
Wu, T., Yoon, H., Xiong, Y., Dixon-Clarke, S. E., Nowak, R. P., & Fischer, E. S. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-020-0438-0 · Cited by 180
Von Hippel–Lindau disease: insights into oxygen sensing, protein degradation, and cancer
Kaelin, W. G. (2022) · Journal of Clinical Investigation · doi:10.1172/jci162480 · Cited by 161
Du, X., Volkov, O. A., Czerwinski, R. M., Tan, H., Huerta, C., Morton, E. R., Rizzi, J. P., Wehn, P. M., Xu, R., Nijhawan, D., et al. (2019) · Structure · doi:10.1016/j.str.2019.10.005 · Cited by 181
Self-citationTargeting mRNA processing as an anticancer strategy
Desterro, J., Bak-Gordon, P., & Carmo-Fonseca, M. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0042-3 · Cited by 181
Ginno, P. A., Gaidatzis, D., Feldmann, A., Hoerner, L., Imanci, D., Burger, L., Zilbermann, F., Peters, A. H. F. M., Edenhofer, F., Smallwood, S. A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16354-x · Cited by 171
From Thalidomide to Rational Molecular Glue Design for Targeted Protein Degradation
Oleinikovas, V., Gainza, P., Ryckmans, T., Fasching, B., & Thomä, N. H. (2024) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-022123-104147 · Cited by 178
E3 ligase ligand chemistries: from building blocks to protein degraders
Sosič, I., Bricelj, A., & Steinebach, C. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00148a · Cited by 163
Haven't got a glue: Protein surface variation for the design of molecular glue degraders
Kozicka, Z., & Thomä, N. H. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.04.009 · Cited by 170
Yamamoto, J., Ito, T., Yamaguchi, Y., & Handa, H. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00116k · Cited by 158
Dysregulation and therapeutic targeting of RNA splicing in cancer
Stanley, R. F., & Abdel-Wahab, O. (2022) · Nature Cancer · doi:10.1038/s43018-022-00384-z · Cited by 161
Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACs
Girardini, M., Maniaci, C., Hughes, S. J., Testa, A., & Ciulli, A. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.02.048 · Cited by 153
From Discovery to Bedside: Targeting the Ubiquitin System
Wertz, I. E., & Wang, X. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2018.10.022 · Cited by 166
Rajapakse, V. N., Luna, A., Yamade, M., Loman, L., Varma, S., Sunshine, M., Iorio, F., Sousa, F. G., Elloumi, F., Aladjem, M. I., et al. (2018) · iScience · doi:10.1016/j.isci.2018.11.029 · Cited by 153
Targeted protein degradation: current and future challenges
Hanzl, A., & Winter, G. E. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.11.012 · Cited by 149
Expanding the arsenal of E3 ubiquitin ligases for proximity-induced protein degradation
Kannt, A., & Đikić, I. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.04.007 · Cited by 142
Template-assisted covalent modification underlies activity of covalent molecular glues
Li, Y.-D., Ma, M. W., Hassan, M. M., Hunkeler, M., Teng, M., Puvar, K., Rutter, J. C., Lumpkin, R. J., Sandoval, B., Jin, C. Y., et al. (2024) · Nature Chemical Biology · doi:10.1038/s41589-024-01668-4 · Cited by 143
An E3 ligase guide to the galaxy of small-molecule-induced protein degradation
Jevtić, P., Haakonsen, D. L., & Rapé, M. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.04.002 · Cited by 143
Altered RNA Processing in Cancer Pathogenesis and Therapy
Obeng, E. A., Stewart, C., & Abdel-Wahab, O. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0399 · Cited by 139
Ohdera, A. H., Abrams, M. J., Ames, C. L., Baker, D. M., Bolívar, L. P. S., Collins, A. G., Freeman, C. J., Gamero-Mora, E., Goulet, T. L., Hofmann, D. K., et al. (2018) · Frontiers in Ecology and Evolution · doi:10.3389/fevo.2018.00035 · Cited by 156
Small-molecule targeting of MUSASHI RNA-binding activity in acute myeloid leukemia
Minuesa, G., Albanese, S. K., Xie, W., Kazansky, Y., Worroll, D., Chow, A., Schurer, A., Park, S., Rotsides, C. Z., Taggart, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10523-3 · Cited by 143
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
Jan, M., Sperling, A. S., & Ebert, B. L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00479-z · Cited by 137
Cowan, A. D., & Ciulli, A. (2022) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-032620-104421 · Cited by 130
Ligandability of E3 Ligases for Targeted Protein Degradation Applications
Belcher, B. P., Ward, C. C., & Nomura, D. K. (2023) · Biochemistry · doi:10.1021/acs.biochem.1c00464 · Cited by 132
Inhibition of RNA-binding proteins with small molecules
Wu, P. (2020) · Nature Reviews Chemistry · doi:10.1038/s41570-020-0201-4 · Cited by 146
Assi, R. E., Kantarjian, H. M., Kadia, T. M., Pemmaraju, N., Jabbour, E. J., Jain, N., Daver, N. G., Estrov, Z. E., Uehara, T., Owa, T., et al. (2018) · Cancer · doi:10.1002/cncr.31398 · Cited by 155
The state of the art of PROTAC technologies for drug discovery
Wang, C., Zheng, C., Wang, H., Zhang, L., Liu, Z., & Xu, P. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114290 · Cited by 115
Chen, H., Liu, J., Kaniskan, H. Ü., Wei, W., & Jin, J. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00901 · Cited by 118
Discovery of E3 Ligase Ligands for Target Protein Degradation
Lee, J., Lee, Y., Jung, Y. M., Park, J. H., Yoo, H. S., & Park, J. (2022) · Molecules · doi:10.3390/molecules27196515 · Cited by 137
Defining molecular glues with a dual-nanobody cannabidiol sensor
Cao, S., Kang, S., Mao, H., Yao, J., Gu, L., & Zheng, N. (2022) · Nature Communications · doi:10.1038/s41467-022-28507-1 · Cited by 125
Toxicomicrobiomics: The Human Microbiome vs. Pharmaceutical, Dietary, and Environmental Xenobiotics
Abdelsalam, N. A., Ramadan, A. T., ElRakaiby, M. T., & Aziz, R. K. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00390 · Cited by 122
Sievers, Q. L., Gasser, J. A., Cowley, G. S., Fischer, E. S., & Ebert, B. L. (2018) · Blood · doi:10.1182/blood-2018-01-821769 · Cited by 124
Aryl Sulfonamides Degrade RBM39 and RBM23 by Recruitment to CRL4-DCAF15
Ting, T. C., Goralski, M., Klein, K., Wang, B., Kim, J., Xie, Y., & Nijhawan, D. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.09.079 · Cited by 123
Self-citationShirasaki, R., Matthews, G. M., Gandolfi, S., de Matos Simoes, R., Buckley, D. L., Raja Vora, J., Sievers, Q. L., Brüggenthies, J. B., Dashevsky, O., Poarch, H., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2020.108532 · Cited by 123
“Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15.”
InfluentialStrategies for designing proteolysis targeting chimaeras (PROTACs)
He, S., Dong, G., Cheng, J., Wu, Y., & Sheng, C. (2022) · Medicinal Research Reviews · doi:10.1002/med.21877 · Cited by 108
Mayor-Ruiz, C., Jaeger, M. G., Bauer, S., Brand, M., Sin, C., Hanzl, A., Mueller, A. C., Menche, J., & Winter, G. E. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.07.013 · Cited by 119
Landmarks of human embryonic development inscribed in somatic mutations
Bizzotto, S., Dou, Y., Ganz, J., Doan, R. N., Kwon, M., Bohrson, C. L., Kim, S. N., Bae, T., Abyzov, A., NIMH Brain Somatic Mosaicism Network, et al. (2021) · Science · doi:10.1126/science.abe1544 · Cited by 117
Selective degradation of multimeric proteins by TRIM21-based molecular glue and PROTAC degraders
Lu, P., Cheng, Y., Xue, L., Ren, X., Xu, X., Chen, C., Cao, L., Li, J., Wu, Q., Sun, S., et al. (2024) · Cell · doi:10.1016/j.cell.2024.10.015 · Cited by 125
Self-citationHuR as a molecular target for cancer therapeutics and immune-related disorders
Majumder, M., Chakraborty, P., Mohan, S., Mehrotra, S., & Palanisamy, V. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114442 · Cited by 130
Design principles for cyclin K molecular glue degraders
Kozicka, Z., Suchyta, D. J., Focht, V., Kempf, G., Petzold, G., Jentzsch, M., Zou, C., Di Genua, C., Donovan, K. A., Coomar, S., et al. (2024) · Nature Chemical Biology · doi:10.1038/s41589-023-01409-z · Cited by 113
Targeting the undruggables—the power of protein degraders
Zhang, C., Liu, Y., Li, G., Yang, Z., Han, C., Sun, X., Sheng, C., Ding, K., & Rao, Y. (2024) · 中国科学通报:英文版 · doi:10.1016/j.scib.2024.03.056 · Cited by 118
Nijhuis, A., Sikka, A., Yogev, O., Herendi, L., Balcells, C., Ma, Y., Poon, E., Eckold, C., Valbuena, G. N., Xu, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28907-3 · Cited by 110
Metadata
- Authors
- Han, T., Goralski, M., Gaskill, N., Capota, E., Kim, J., Ting, T. C., Xie, Y., Williams, N. S., & Nijhawan, D.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Harold C. Simmons Comprehensive Cancer Center (US)
- Corresponding author
- Goralski, Maria
- Gaskill, Nicholas
- Nijhawan, Deepak
- ORCID
- Venue
- Science
- Published
- 2017-04-28
- Volume
- 356
- Issue
- 6336
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2596064219
- Cited by
- 762
- References
- 55
- Citations by year
- 2026: 72 · 2025: 86 · 2024: 122 · 2023: 99 · 2022: 86 · 2021: 99 · 2020: 86 · 2019: 56 · 2018: 40 · 2017: 15
- FWCI
- 22.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Welch Foundation (I-1879)
- Damon Runyon Cancer Research Foundation (CI-68-13)
- Cancer Prevention and Research Institute of Texas (RP150596)
- Life Sciences Research Foundation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- indisulam, sulfonamides, RBM39, DCAF15, pre-mRNA splicing, splicing inhibition, proteasomal degradation, polyubiquitination, anticancer agents, drug resistance, biomarkers
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Mutation, Neoplasms, Nuclear Proteins, RNA Splicing, Sulfonamides, RNA-Binding Proteins, Mice, Knockout, Drug Resistance, Neoplasm, Amino Acid Substitution, Xenograft Model Antitumor Assays, Ubiquitin-Protein Ligase Complexes, Cell Line, Tumor, Proteasome Endopeptidase Complex, Mice, Biomarkers, Pharmacological, Ubiquitination, Molecular Targeted Therapy, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.